Conference Coverage

Pulsed field ablation challenges conventional devices in AFib


 

FROM THE ESC CONGRESS 2023

Procedure time faster with PFA

Despite working with a new technology, the mean procedure performance time with PFA was faster (105 vs. 123 minutes) even though mean fluoroscopy time was longer (21.1 vs 13.9 minutes). Dr. Reddy considers the difference in procedure time a meaningful demonstration of the efficiency of PFA.

“When you look at procedure performance, it is remarkable that the procedure times were statistically significantly shorter for a first-use technology in the hands of multiple operators,” Dr. Reddy said.

There was also a statistically significant advantage for PFA regarding change in the mean pulmonary vein cross-sectional area following the procedures (0.9% vs. 12%). Dr. Reddy acknowledged that small changes in pulmonary vein dimension are not clinically meaningful, but this result “gets at the question of whether we can achieve ablation without tissue proliferation that we see with conventional ablation.”

Overall, Dr. Reddy believes that the data from ADVENT provide several reasons “to get excited about PFA,” including the efficiency of this technique in the context of at least similar efficacy but a potential for fewer adverse events.

The ESC-invited discussant, Samuel Kiil Sørensen, MD, Gentofte University Hospital, Copenhagen, agreed that the ADVENT data support PFA as an alternative to thermal ablation. He suggested that the shorter procedure times are clinically meaningful given comparable safety and efficacy.

“Which property of PFA justifies noninferiority?” he asked. “Many of the complications of AF ablation are not specific to the energy modality. The devastating complications from damage to the esophagus, pulmonary veins, and phrenic nerve that the PFA technology may eliminate are rare, so they would not be expected to change the overall complication rate in a [randomized controlled trial] of realistic size.”

However, he suggested PFA might still prove to be an incremental advance for AF. He cited previous evidence that supports the specificity of its ablative activity and emphasized that ADVENT tested a first-generation device that might not capture the full advantages of the PFA technology.

The trial was supported by Farapulse–Boston Scientific. Dr. Reddy reports financial relationships with more than 30 pharmaceutical or device manufacturers, including Farapulse–Boston Scientific. Dr. Sørensen reports financial relationships with Medtronic and Biosense Webster.

A version of this article first appeared on Medscape.com.

Pages

Next Article: